Acute Leukemias - Republican Scientific Medical Library

166 Chapter 12 · ALL Therapy: Review of the MD Anderson Program
12.4 Summary
The developments of dose-intensive, multiagent therapy
programs, which were patterned after experience in
childhood ALL have created the current standard of
approach in adult ALL. Further improvement will depend
on dissecting the biologic heterogeneity of ALL
further, identifying targets for therapy, and developing
novel agents in clinical trials. The goal of these developments
remains subtype-specific and risk-adapted therapy,
which will eventually improve long-term outcome
for adults with ALL.
References
1. Murphy SB, Bowman WP, Abromowitch M, et al. (1986) Results of
treatment of advanced-stage Burkitt’s lymphoma and B cell (sIg+)
acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide
and coordinated high-dose methotrexate and cytarabine.
J Clin Oncol 4:1732–1739
2. Bagley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology
of cyclphosphamide. Cancer Res 33:226–233
3. Iversen OH, Iversen U, Ziegler JL, et al. (1974) Cell kinetics in Burkitt
lymphoma. Eur J Cancer 10:155–163
4. Garcia-Manero G, Kantarjian HM (2000) The hyper-CVAD regimen
in adult acute lymphocytic leukemia. Hematol Oncol Clin North
Am 6:1381–1396
5. Childhood ALL Collaborative Group (1996) Duration and intensity
of maintenance chemotherapy in acute lymphoblastic leukaemia:
Overview of 42 trials involving 12000 randomized children. Lancet
347:1783–1788
6. Dekker AW, van’t Veer MB, Sizoo W, et al. (1997) Intensive postremission
chemotherapy without maintenance therapy in adults
with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research
Group. J Clin Oncol 15:476–482
7. Kantarjian HM, O’Brien S, Smith TL, et al. (2000) Results of treatment
with hyper-CVAD, a dose-intensive regimen, in adult acute
lymphocytic leukemia. J Clin Oncol 18:547–561
8. Kantarjian HM, O’Brien S, Smith T, et al. (1994) Acute lymphocytic
leukaemia in the elderly: Characteristics and outcome with the
vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol
88:94–100
9. Todeschini G, Tecchio C, Meneghini V, et al. (1998) Estimated 6year
event-free survival of 55% in 60 consecutive adult acute lymphoblastic
leukemia patients treated with an intensive phase II
protocol based on high induction dose of daunorubicin. Leukemia
12:144–149
10. Thomas DA, Cortes J, O’Brien S, et al. (2000) Significance of CD20
positivity in de novo acute lymphocytic leukemia (ALL). Blood
96:109a
11. Thomas DA, Cortes J, Giles F, et al. (2003) Update of the modified
hyper-CVAD regimen in newly diagnosed adult acute lymphocytic
leukemia (ALL). Blood 102:880a
12. Dombret H, Gabert J, Boiron J-M, et al. (2002) Outcome of treatment
in adults with Philadelphia chromosome-positive acute lymphoblastic
leukemia7Results of the prospective multicenter
LALA-94 trial. Blood 100:2357–2366
13. Faderl S, Kantarjian HM, Thomas DA, et al. (2000) Outcome of Philadelphia
chromosome-positive adult acute lymphoblastic leukemia.
Leuk Lymphoma 36:263–273
14. Druker BJ, Sawyers CL, Kantarjian H, et al. (2001) Activity of a specific
inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of
chronic myeloid leukemia and acute lymphoblastic leukemia with
the Philadelphia chromosome. N Engl J Med 344:1038–1042
15. Ottmann OG, Druker BJ, Sawyers CL, et al. (2002) A phase 2 study
of imatinib in patients with relapsed or refractory Philadelphia
chromosome-positive acute lymphoid leukemias. Blood
100:1965–1971
16. Ottmann OG, Wassmann B, Pfeifer H, et al. (2004) Imatinib given
concurrently with induction chemotherapy is superior to imatinib
subsequent to induction and consolidation in newly diagnosed
Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Blood 104:197a
17. Towatari M, Yanada M, Usui N, et al. (2004) Combination of intensive
chemotherapy and imatinib can rapidly induce high-quality
complete remission for a majority of patients with newly diagnosed
BCR-ABL-positive acute lymphoblastic leukemia. Blood
104:3507–3512
18. Thomas DA, Faderl S, Cortes J, et al. (2004) Treatment of Philadelphia
chromosome-positive acute lymphocytic leukemia with hyper-CVAD
and imatinib mesylate. Blood 103:4396–4407
19. Thomas DA, Faderl S, Cortes J, et al. (2004) Update of the Hyper-
CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive
acute lymphocytic leukemia (ALL). Blood 104:748a
20. Gill PS, Meyer PR, Pavlova Z, et al. (1986) B cell acute lymphoblastic
leukemia in adults. Clinical, morphological, and immunologic
findings. J Clin Oncol 4:737–743
21. Fenaux P, Bourhuis JH, Ribrag V (2001) Burkitt’s acute lymphocytic
leukemia (L3 ALL) in adults. Hematol Oncol Clin North Am 15:37–
50
22. Patte C, Philip T, Rodary C, et al. (1986) Improved survival rate in
children with stage III and stage IV B cell non-Hodgkin’s lymphoma
and leukemia using multi-agent chemotherapy: Results of a
study of 114 children from the French Pediatric Oncology Society.
J Clin Oncol 4:1219–1226
23. Reiter A, Schrappe M, Ludwig W-D, et al. (1992) Favorable outcome
of B-cell acute lymphoblastic leukemia in childhood: A report
of three consecutive studies of the BFM group. Blood
80:2471–2478
24. Thomas DA, Cortes J, Faderl S, et al. (2005) Hyper-CVAD and rituximab
therapy in HIV-negative Burkitt (BL) or Burkitt-like (BLL) leukemia/lymphoma
and mature B-cell acute lymphocytic leukemia
(B-ALL). J Clin Oncol 23(16S):567s
25. Cortes J, Thomas D, Rios A, et al. (2002) Hyperfractionated cyclophosphamide,
vincristine, doxorubicin, and dexamethasone and
highly active antiretroviral therapy for patients with acquired immunodeficiency
syndrome-related Burkitt lymphoma/leukemia.
Cancer 94:1492–1499